Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50 to 75 with Intermediate-2 and High-Risk Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 Study Rationale, Design, and Methods

Document Details

Document Type
Pub Defense Publication
Publication Date
Oct 01, 2014
Source ID
10.1016/j.bbmt.2014.06.010

Entities

People

  • Adam Mendizabal
  • Brent Logan
  • Corey S. Cutler
  • Eric Leifer
  • Frederick R. Appelbaum
  • Jennifer Le Rademacher
  • Mary M. Horowitz
  • Mikkael Sekeres
  • Moira Lewis
  • Ryotaro Nakamura
  • Wael Saber

Organizations

  • ARIAD Pharmaceuticals
  • Amgen
  • Blue Cross Blue Shield Association
  • Celgene
  • Elevance Health, Inc.
  • GSK
  • Kiadis Pharma (Netherlands)
  • Leukemia & Lymphoma Society
  • Medical College of Wisconsin
  • Merck & Co.
  • National Cancer Institute
  • National Heart, Lung, and Blood Institute
  • National Institute of Allergy and Infectious Diseases
  • National Marrow Donor Program
  • Office of Naval Research
  • Onyx Pharmaceuticals
  • Osiris Therapeutics
  • Otsuka (United States)
  • Roche (United States)
  • Sanofi-Aventis
  • Seagen
  • Sigma-Tau Pharmaceuticals (United States)
  • StemCyte
  • Swedish Orphan Biovitrum
  • Tarix Orphan (United States)
  • Terumo BCT (United States)
  • Texas Instruments

Tags

Technology Areas

  • Biotechnology